

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

**Name of entity**

**BENITEC BIOPHARMA LIMITED**

**ABN**

64 068 943 662

**Quarter ended ("current quarter")**

30 June 2018

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	37	237
1.2 Payments for		
(a) research and development	(1,631)	(6,361)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(1,083)	(4,882)
(f) administration and corporate costs	(558)	(3,255)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	53	246
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	4,112
1.8 Other (refund of CRO prepayment)	-	109
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(3,182)</b>	<b>(9,794)</b>

**Appendix 4C**  
**Quarterly report for entities subject to Listing Rule 4.7B**

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(3)	(83)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	2
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (deposits)	38	(66)
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>35</b>	<b>(147)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares	8,821	8,821
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	(313)	(313)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (capital raising cost)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>8,508</b>	<b>8,508</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	10,535	17,375
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,182)	(9,794)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	35	(146)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	8,508	8,508
4.5	Effect of movement in exchange rates on cash held	189	142
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>16,085</b>	<b>16,085</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	9,575	9,575
5.2	Call deposits	6,510	6,510
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>16,085</b>	<b>16,085</b>

Subsequent Event - US\$10m (AUD\$13.5m) upfront payment was received from Axovant on 19 July 2018.

**Appendix 4C**  
**Quarterly report for entities subject to Listing Rule 4.7B**

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
71
nil

Payments related to directors' fees (\$70k) and payments to related party (\$1k)

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000
9.6
-

Annabel West, the wife of Greg West, our Chief Executive Officer, was employed by Benitec as a part-time clerical and administrative assistant. Annabel West was paid wages of \$9.6k for the March quarter. Greg West resigned on 15 June, 2018.

**8. Financing facilities available**

*Add notes as necessary for an understanding of the position*

- 8.1 Loan facilities
- 8.2 Credit standby arrangements
- 8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.


9.	Estimated cash outflows for next quarter	\$A'000
9.1	Research and development *	* 4,010
9.2	Product manufacturing and operating costs	-
9.3	Advertising and marketing	-
9.4	Leased assets	-
9.5	Staff costs	1,237
9.6	Administration and corporate costs	983
9.7	Other (provide details if material)	129
<b>9.8</b>	<b>Total estimated cash outflows</b>	<b>6,359</b>

\* Research and Development costs comprise several payments including large one off payments. The timing of these payments has inherent uncertainty and actual payment timings may differ from the forecast period. Changes in the expected timing of these payments may materially affect forecast quarterly cashflows.

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration	N/A	N/A
10.3	Consideration for acquisition or disposal	N/A	N/A
10.4	Total net assets	N/A	N/A
10.5	Nature of business	N/A	N/A

**Compliance statement**

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  .....  
(Director)

Date: 31 July 2018

Print name: .....Megan Boston.....

**Notes**

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.